Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Schiller, M. J. Articles by Hargreaves, W. A. Search for Related Content PubMed Citation Articles by Schiller, M. J. Articles by Hargreaves, W. A. Costs, Cost Analysis Outcome and Process Assessment

Treatment Costs and Patient Outcomes With Use of Risperidone in a Public Mental Health Setting

OBJECTIVE: Risperidone's effectiveness in reducing symptoms and its cost were compared with the effectiveness and cost of standard antipsychotic medication among matched groups of outpatients with schizophrenia. METHODS: Data on 56 subjects started on risperidone were compared with data for a matched group of 56 subjects over the 12 months before and after initiation of risperidone. Global Assessment of Functioning (GAF) scores were used to assess effectiveness. Service utilization data were used to calculate the cost of treatment. RESULTS: Total treatment costs for the two groups were not significantly different, although there was a trend toward higher costs in the risperidone group. Monthly GAF scores revealed no group differences in the effectiveness of the medications. CONCLUSIONS: No significant differences in treatment effectiveness or costs were found between the risperidone and comparison groups, despite a trend to higher treatment costs for the risperidone group.

This article has been cited by other articles:

				G. G Liu, S. X Sun, D. B Christensen, and X. Luo Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia Ann. Pharmacother., January 1, 2004; 38(1): 134 - 141. [Abstract] [Full Text] [PDF]

				D. L. Noordsy, C. O'Keefe, K. T. Mueser, and H. Xie Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment Psychiatr Serv, April 1, 2001; 52(4): 501 - 507. [Abstract] [Full Text] [PDF]

				D. Mossman and D. S. Lehrer Conventional and Atypical Antipsychotics and the Evolving Standard of Care Psychiatr Serv, December 1, 2000; 51(12): 1528 - 1535. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us